Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

NCT01200004 ↗

Phase 1 Terminated 1 enrolled M.D. Anderson Cancer Center Yukiguni Maitake Company Ltd. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of Grifola frondosa extract, azacitidine, and lenalidomide that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Timeline

Start: 2012-04
Primary completion: 2013-07
Completion: 2013-07

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitidine	Other / unclassified	75 mg/m2	Subcutaneous
Subject	Grifola Frondosa	Unknown	3 mg/kg	Oral
Subject	Lenalidomide	Other / unclassified	10 mg	Oral

Indications

No indication recorded.